Literature DB >> 10510393

IL-15 prolongs the duration of CD8+ T cell-mediated immunity in mice infected with a vaccine strain of Toxoplasma gondii.

I A Khan1, L Casciotti.   

Abstract

Immunization of mice with a vaccine (ts-4) strain of Toxoplasma gondii is known to induce complete protection against subsequent lethal infection. Ts-4-mediated protection has been reported to be primarily dependent on IFN-gamma-producing CD8+ T cells. However, duration of CD8+ T cell-mediated immunity in the ts-4-vaccinated animals is not known. In the present study, the kinetics of the CD8+ T cell response in mice immunized with the ts-4 strain of T. gondii was evaluated. Optimal CD8+ T cell immunity persisted at least 6 mo after vaccination, and mice at this time point continued to overcome lethal challenge with a more virulent strain. However, at 9 mo postimmunization, CD8+ T cell immunity was severely diminished and the mice succumbed to Toxoplasma challenge. Pretreatment of animals, vaccinated 9 mo earlier, with rIL-15 prevented the mortality induced by Toxoplasma challenge. The protective effect of IL-15 treatment was due to a rise in the frequency of Ag-specific CD8+ T cells. CD8+ T cells from IL-15-administered animals showed increased proliferation and IFN-gamma production in response to antigenic restimulation. These findings suggest that rIL-15 can reverse the decline in the long-term CD8+ T cell immune response in mice immunized with vaccine strain of T. gondii.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10510393

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  CD8(+)-T-cell immunity against Toxoplasma gondii can be induced but not maintained in mice lacking conventional CD4(+) T cells.

Authors:  Lori Casciotti; Kenneth H Ely; Martha E Williams; Imtiaz A Khan
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

2.  IL-15-induced conversion of monocytes to mature dendritic cells.

Authors:  K U Saikh; A S Khan; T Kissner; R G Ulrich
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

Review 3.  Apoptosis and the balance of homeostatic and pathologic responses to protozoan infection.

Authors:  L Cristina Gavrilescu; Eric Y Denkers
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

4.  The use of CpG as an adjuvant to Toxoplasma gondii vaccination.

Authors:  Jennifer A Spencer; Bruce F Smith; Anthony J Guarino; Byron L Blagburn; Henry J Baker
Journal:  Parasitol Res       Date:  2004-01-15       Impact factor: 2.289

Review 5.  Concepts of immunostimulation to increase antiparasitic drug action.

Authors:  K Noel Masihi
Journal:  Parasitol Res       Date:  2003-01-08       Impact factor: 2.289

6.  Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool.

Authors:  Fraia Melchionda; Terry J Fry; Matthew J Milliron; Melissa A McKirdy; Yutaka Tagaya; Crystal L Mackall
Journal:  J Clin Invest       Date:  2005-04-07       Impact factor: 14.808

7.  Lack of IL-15 results in the suboptimal priming of CD4+ T cell response against an intracellular parasite.

Authors:  Crescent L Combe; Magali M Moretto; Joseph D Schwartzman; Jason P Gigley; David J Bzik; Imtiaz A Khan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-13       Impact factor: 11.205

8.  Utilizing IL-12, IL-15 and IL-7 as Mucosal Vaccine Adjuvants.

Authors:  Liljana Stevceva; Marcin Moniuszko; Maria Grazia Ferrari
Journal:  Lett Drug Des Discov       Date:  2006       Impact factor: 1.150

9.  IL-15 converts human intestinal intraepithelial lymphocytes to CD94 producers of IFN-gamma and IL-10, the latter promoting Fas ligand-mediated cytotoxicity.

Authors:  Ellen C Ebert
Journal:  Immunology       Date:  2005-05       Impact factor: 7.397

10.  The survival of memory CD8 T cells that is mediated by IL-15 correlates with sustained protection against malaria.

Authors:  Stasya Zarling; Dmitriy Berenzon; Sarat Dalai; Dmitry Liepinsh; Nick Steers; Urszula Krzych
Journal:  J Immunol       Date:  2013-04-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.